Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.41 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.41 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.41 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436327 | 0.88 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL19286172 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTGAAGLA | |
| SCHEMBL7715325 | 0.81 | MAPT (0.51) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL4125050 | 0.79 | KDM4E (0.49) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL20436313 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL10609908 | 0.78 | KDM4E (0.54) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL20441471 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL12348758 | 0.76 | ROCK2 (0.41) | ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL6053373 | 0.75 | RXFP1 (0.46) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL12064530 | 0.75 | GAA (0.47) | ALDH1A1KDM4EMAPTHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11327060-B2 | Method for analyzing enantiomer | AJINOMOTO CO., INC. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-11327060-B2 | Method for analyzing enantiomer | AJINOMOTO CO., INC. (JP) | 2022-05-10 | — | — | US | disclosed |
| EP-3358346-B1 | ENANTIOMER ANALYSIS METHOD | AJINOMOTO KK (JP) | 2022-01-19 | — | — | EP | disclosed |
| EP-3358346-B1 | ENANTIOMER ANALYSIS METHOD | AJINOMOTO KK (JP) | 2022-01-19 | — | — | EP | disclosed |
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| EP-3358346-A1 | ENANTIOMER ANALYSIS METHOD | Ajinomoto Co., Inc. (JP) | 2018-08-08 | — | — | EP | disclosed |
| EP-3358346-A1 | ENANTIOMER ANALYSIS METHOD | Ajinomoto Co., Inc. (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-20180217113-A1 | METHOD FOR ANALYZING ENANTIOMER | AJINOMOTO CO., INC. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20180217113-A1 | METHOD FOR ANALYZING ENANTIOMER | AJINOMOTO CO., INC. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20180217113-A1 | METHOD FOR ANALYZING ENANTIOMER | AJINOMOTO CO., INC. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-01-25 | — | — | US | disclosed |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-01-25 | — | — | US | disclosed |
| US-8084641-B2 | Organocataslysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090088588-A1 | Organocatalysts and methods of use in chemical synthesis | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11327060-B2 | Method for analyzing enantiomer | DCX, INF2, SRD5A2 | ALDH1A1 834/4885KDM4E 3290/4885MAPT 3206/4885 |
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | MME, ACE, REN | ALDH1A1 934/4885KDM4E 2269/4885MAPT 326/4885 |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | MME, ACE, REN | ALDH1A1 934/4885KDM4E 2269/4885MAPT 326/4885 |
| US-20180217113-A1 | METHOD FOR ANALYZING ENANTIOMER | DCX, INF2, SRD5A2 | ALDH1A1 834/4885KDM4E 3290/4885MAPT 3206/4885 |
| US-20090088588-A1 | Organocatalysts and methods of use in chemical synthesis | ICMT, PPOX, CYP4F3 | ALDH1A1 1418/4885KDM4E 2323/4885MAPT 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.